Cytokine gene polymorphism might affect the outcome of clinical rejection in cardiac transplantation.

Autor: McDaniel DO, Roten DP, Yamout SZ, Coleman V, Aru G, Heath B, Thomas TS, Turner WW Jr., Chatham TF, Cameron JA, Moore CK
Zdroj: Journal of Applied Research; Winter2004, Vol. 4 Issue 1, p68-80, 13p
Abstrakt: Introduction: Cardiac allograft rejection is associated with an individual's inflammatory cytokine gene polymorphism. It was hypothesized that possession of specific cytokine alleles might be influential in predisposing the recipient to allograft rejection.Methods: DNA from nucleated peripheral blood cells of 65 cardiac transplantation patients and 77 controls were tested for IL-2, TNF-alpha TGF-(beta1, IL-10,IL-6, and IFN-gamma gene polymorphism by polymerase chain reaction. Genotype variation was analyzed in view of the recipient's clinical condition and histopathological assessment for rejection. Transplant rejection was determined by endomyocardial biopsy and scored 1A, 2, and 3A/3B.Results: Overall, 57% of recipients at pre-transplantation suffered from ischemic-cardiomyopathy; whereas 43% had some form of non-ischemic-cardiomyopathy. There were fewer IL-10 high producer genotypes in recipients with 2 and 3A/3B rejection scores than in those with 1A scores (28.6% vs. 22.6% vs. 80%; P<0.01 respectively).Introduction: Cardiac allograft rejection is associated with an individual's inflammatory cytokine gene polymorphism. It was hypothesized that possession of specific cytokine alleles might be influential in predisposing the recipient to allograft rejection.Methods: DNA from nucleated peripheral blood cells of 65 cardiac transplantation patients and 77 controls were tested for IL-2, TNF-alpha TGF-(beta1, IL-10,IL-6, and IFN-gamma gene polymorphism by polymerase chain reaction. Genotype variation was analyzed in view of the recipient's clinical condition and histopathological assessment for rejection. Transplant rejection was determined by endomyocardial biopsy and scored 1A, 2, and 3A/3B.Results: Overall, 57% of recipients at pre-transplantation suffered from ischemic-cardiomyopathy; whereas 43% had some form of non-ischemic-cardiomyopathy. There were fewer IL-10 high producer genotypes in recipients with 2 and 3A/3B rejection scores than in those with 1A scores (28.6% vs. 22.6% vs. 80%; P<0.01 respectively). [ABSTRACT FROM AUTHOR]
Databáze: Supplemental Index